Ulcerative colitis (UC) is an inflammatory bowel disease that is generally insurable at standard or near-standard rates when in remission. Active disease, frequent flares, or complications such as colorectal cancer history or significant surgical history affect the underwriting outcome. Disease activity, medication regimen, surgical history, and colon cancer screening compliance are the variables that drive everything.
What Underwriters Evaluate for Ulcerative Colitis
UC Profile: General Underwriting Outlook
| UC Profile | Typical Rating | Best Achievable | Notes |
|---|---|---|---|
| Confirmed remission, mild disease, mesalamine only | Standard to Table 2 | Standard at many carriers | Mild UC in remission is widely insurable at favorable rates |
| Moderate disease in remission, biologic therapy | Table 2–4 | Table 2 | Biologic adds rating but remains insurable in remission |
| Severe disease history, frequent hospitalizations | Table 4–8 | Table 4 in documented remission | History of severity matters even if currently in remission |
| Active disease at time of application | Postponement | Postponement until remission | Apply when in confirmed remission for best outcome |
Guidelines current as of 2025–2026. Verify with us before applying.
Have Ulcerative Colitis? Let’s Find Your Best Rate.
UC in remission is broadly insurable at competitive rates. We match your disease profile to the right carrier and identify your best option before any application is submitted.
Browse All High-Risk Conditions
Atrial Fibrillation | Heart Attack / Heart Disease | High Blood Pressure | Stroke / TIA | Diabetes | Obesity | Thyroid Disease | COPD / Emphysema | Sleep Apnea | Lupus | Multiple Sclerosis | Rheumatoid Arthritis | Kidney Disease (CKD) | Hepatitis B & C | Crohn’s Disease | Cancer History | Anxiety / Depression | Bipolar Disorder | Epilepsy | PTSD | HIV / AIDS | DUI / DWI | Drug Use / Abuse | Marijuana Use | Aviation / Pilots
Understanding Your Rating: Life Insurance Risk Classifications | Table Ratings Explained (B–J) | Flat Extra Ratings
Authoritative Resources: Life insurance underwriting practices are regulated by the NAIC. Insurers may check your health history through the MIB Group — you can request your free annual MIB report at mib.com.
Frequently Asked Questions
Can I get life insurance with ulcerative colitis?
Yes. Ulcerative colitis in documented remission is broadly insurable at favorable rates. Mild UC managed with aminosalicylates and confirmed in remission by colonoscopy can qualify for standard or near-standard rates at many carriers. Active disease at the time of application typically results in postponement until remission is established.
Does UC in remission qualify for standard life insurance rates?
Yes. Mild to moderate UC in confirmed remission — ideally supported by recent colonoscopy showing quiescent disease — can qualify for standard rates at many major carriers. Moderate UC on biologic therapy in remission typically results in Table 2 to Table 4. The key is documented remission at the time of application.
How does biologic therapy for UC affect underwriting?
Biologics such as adalimumab or vedolizumab signal moderate to severe UC requiring more aggressive treatment. However, a good remission response on biologics is still broadly insurable at most carriers, typically at Table 2 to Table 4. Carriers evaluate the current disease state and treatment response more than the specific medication used.
Does a colectomy for ulcerative colitis affect life insurance?
A colectomy performed for UC that has successfully resolved symptoms may actually improve the underwriting outcome compared to active medically managed disease. Post-colectomy applicants with stable health and no ongoing GI complications are evaluated on their current health status, which is often more favorable than ongoing medication-managed active disease.
Does UC increase my life insurance rates due to colorectal cancer risk?
Long-standing ulcerative colitis carries an elevated colorectal cancer risk, which underwriters are aware of. Regular surveillance colonoscopy as recommended — with clean results and no dysplasia — is viewed positively and demonstrates active risk management. Gaps in recommended surveillance or concerning pathology findings such as dysplasia can affect the underwriting outcome.